Last reviewed · How we verify

NAFT600 (adult)

Merz North America, Inc. · FDA-approved active Small molecule

NAFT600 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.

NAFT600 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions. Used for Temporary improvement of moderate to severe glabellar lines (frown lines) in adults, Temporary improvement of moderate to severe lateral canthal lines (crow's feet) in adults.

At a glance

Generic nameNAFT600 (adult)
Also known asNAFT600, naftifine, naftifine hydrochloride
SponsorMerz North America, Inc.
Drug classBotulinum toxin type A
TargetSNARE complex (acetylcholine release machinery)
ModalitySmall molecule
Therapeutic areaAesthetics; Neurology
PhaseFDA-approved

Mechanism of action

Botulinum toxin type A irreversibly cleaves SNARE proteins required for acetylcholine vesicle release, leading to temporary paralysis of injected muscles. This mechanism is used therapeutically to reduce dynamic wrinkles and treat various conditions involving muscle hyperactivity. The effect is temporary, typically lasting 3-4 months, after which neuromuscular function gradually recovers.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: